By Dr Ibon Garitaonandia (CellProthera)2023-07-27T11:00:27
Cell-based therapies have the potential to regenerate heart tissue as an alternative to heart transplants. Here, Dr Ibon Garitaonandia, Chief Scientific Officer at CellProthera, shares how CD34+ cells are demonstrating promising results in clinical studies.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-01-29T15:00:00 2026-01-29T16:00:00
Sponsored by Thermo Fisher Scientific
2026-05-27T14:00:00 2026-05-27T15:00:00
Sponsored by TA Instruments
2026-03-26T15:00:00 2026-03-26T16:00:00
Sponsored by Medable
2025-09-24T15:24:00
Sponsored by Lonza
2026-02-09T10:00:00 2026-02-09T11:00:00
Sponsored by Emerson
Site powered by Webvision Cloud